U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON and SHANGHAI - U.S. FDA issued Sichuan Pharmaceutical Co., Ltd. a warning letter Sept. 9 for significant deviations from current good manufacturing practices in the manufacture of active pharmaceutical ingredients. The warning letter adds more woes to the troubled China state-owned enterprise, and the Chengdu government is looking for a basement price to unload the company